Crisaborole is a boron compound recently approved by the US Food and Drug Administration as a 2% ointment for the treatment of mild to moderate atopic dermatitis. This work describes a simple method for the quantification of the drug in the skin layers at the end of in-vitro permeation experiments. Chromatographic separation was carried out on a reverse-phase C18 column using a mixture of trifluoroacetic acid 0.05%–acetonitrile (55:45, v/v) as mobile phase, pumped at 1 ml/min. Column temperature was 35°C and UV detection was performed at 250 nm. The method was linear in the range of concentration from 0.06 to 6 μg/ml (R2 = 1) and was selective, precise and accurate. Depending on the solvent used, the LOQ ranged from 0.014 to 0.030 μg/ml and the LOD from 0.005 to 0.010 μg/ml. The extraction from all the skin layers was quantitative. The developed method was successfully tested in an in-vitro permeation study, proving to be an effective tool in the development of new formulations containing crisaborole.
Development and validation of a simple method for the extraction and quantification of crisaborole in skin layers / Demurtas, A.; Pescina, S.; Nicoli, S.; Santi, P.; Padula, C.. - In: BIOMEDICAL CHROMATOGRAPHY. - ISSN 0269-3879. - (2019), p. e4664. [10.1002/bmc.4664]
|Appare nelle tipologie:||1.1 Articolo su rivista|